Assoc. Prof. SERKAN AKIN

Publication Network

Articles 49

1. Cell therapy in sarcoma: Current landscape and future directions

Sahin T. K., Germetaki T., GÜVEN D. C., AKIN S., DİZDAR Ö., Thistlethwaite F., et al.

Journal for ImmunoTherapy of Cancer , vol.14, no.1, 2026 (SCI-Expanded, Scopus)

2. Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross-Sectional Study

ŞAHİN T. K., Sahin E. A., Gungor H. N., GÜVEN D. C., BARIŞTA İ., AKIN S.

CANCER MEDICINE , no.7, 2025 (SCI-Expanded, Scopus)

3. Serum Albumin-Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with Cancer

BAŞ O., Guduk N., Tokatli M., Guven D. C., ÖZER N., ŞENER Y. Z., et al.

JOURNAL OF CLINICAL MEDICINE , no.5, 2025 (SCI-Expanded, Scopus)

4. The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas

YAZICI G., AKIN S., KAHVECİOĞLU A., YİĞİT E., TÜRKER F. A., YILDIZ F.

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK , no.3, pp.891-898, 2025 (SCI-Expanded, Scopus)

5. Evaluating Immunotherapy Responses in Neuro-Oncology for Glioblastoma and Brain Metastases: A Brief Review Featuring Three Cases

KERTMEN N., KAVGACI G., AKIN S., ÇOBAN ÇİFÇİ G., IŞIKAY A. İ., YAZICI G.

CANCER CONTROL , 2025 (SCI-Expanded, Scopus)

6. Comprehensive analysis of orbital lymphoma in a Turkish cohort: clinical characteristics, histological subtypes, treatment modalities, prognostic factors, and implications for management

AKYILDIZ A., Ismayilov R., Rustamova N., Tokatli M., KOÇ İ., AKIN S., et al.

Annals of Hematology , vol.103, no.3, pp.905-915, 2024 (SCI-Expanded, Scopus)

7. Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation

Ucgul E., Guven D. C., Ucgul A. N., ÖZBAY Y., ONUR M. R., AKIN S.

CANCER CONTROL , vol.31, 2024 (SCI-Expanded, Scopus)

8. Bilateral Testicular Plasmacytoma Preceding Multiple Myeloma with Extramedullary Renal Involvement: A Case Report

KAVGACI G., KÖKSAL B., ARIK Z., BARIŞTA İ., AKIN S.

PLASMATOLOGY , vol.18, 2024 (ESCI, Scopus)

9. Bilgisayarlı Tomografi, Pozitron Emisyon Tomografisi ve Nükleer Manyetik Rezonans Görüntülemede Temel Kavram ve İlkeler.

BAYARI S. H., AKIN S., TUNCEL M.

Batı Karadeniz Tıp Degisi , vol.7, no.3, pp.269-278, 2023 (TRDizin)

10. Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future

Srour S. A., AKIN S.

Journal of Immunotherapy and Precision Oncology , vol.6, no.1, pp.19-30, 2023 (Scopus)

11. A Novel Tumor Marker for Anaplastic Lymphoma Kinase (+) Lymphoma: Beta-Human Chorionic Gonadotropin

Moral K., SEYHAN E., KUTLAY D. Y., AKIN S.

Journal of Oncological Science , vol.9, no.1, pp.46-49, 2023 (Scopus, TRDizin)

12. Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review

YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., et al.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY , vol.15, no.4, pp.307-310, 2022 (ESCI, Scopus)

13. SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research

GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.

ONCOLOGIST , vol.27, no.11, 2022 (SCI-Expanded, Scopus) Sustainable Development

14. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination

GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.

ONCOLOGIST , vol.27, 2022 (SCI-Expanded, Scopus)

15. Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement

Akin S., Hosing C., Khouri I., Ahmed S., Alousi A., Fowler N., et al.

BLOOD ADVANCES , vol.6, no.7, pp.2267-2274, 2022 (SCI-Expanded, Scopus)

16. Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement

Kupik O., Akin S., Tuncel M., Eren G., Türker A., Kars A., et al.

NUCLEAR MEDICINE COMMUNICATIONS , vol.41, no.6, pp.540-549, 2020 (SCI-Expanded, Scopus)

17. Gemcitabine, Oxaliplatin and Paclitaxel (GemPOx ) in Patients with Relapsed or Refractory Germ Cell Tumors After High Dose Chemotherapy, A Retrospective Single-Center Experience

Acar R., Erturk I., Kiziloz H., Okcelik S., Yildiz B., Aykan M. B., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.30, no.4, pp.191-196, 2020 (SCI-Expanded, Scopus, TRDizin)

18. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study

Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., Ates O., et al.

JOURNAL OF BUON , vol.24, no.6, pp.2327-2332, 2019 (SCI-Expanded, Scopus)

19. Association between androgen receptor status and prognosis in triple negative breast cancer

Sunar V., Dogan H. T., Sarici F., ATEŞ Ö., AKIN S., BAŞPINAR B., et al.

JOURNAL OF BUON , vol.23, no.5, pp.1325-1330, 2018 (SCI-Expanded, Scopus)

20. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma

AKIN S., DİZDAR Ö., KARAKAS Y., Turker A., Kars A.

CURRENT PROBLEMS IN CANCER , vol.42, no.3, pp.344-349, 2018 (SCI-Expanded, Scopus)

21. Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms

AKIN S., DİZDAR Ö., Hayran M.

ANNALS OF SURGICAL ONCOLOGY , vol.24, 2017 (SCI-Expanded, Scopus)

22. Farklı Trombositopeni Sebeplerinin Klinik ve Laboratuvar Bulguları

AKIN S., AKIN Ş., Karaağaç A. T., HAZNEDAROĞLU İ. C.

Journal of Contemporary Medicine , vol.7, no.4, pp.316-322, 2017 (Peer-Reviewed Journal)

23. Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database

DİZDAR Ö., BİLGİN E., AKIN S., KILIÇKAP S., HAYRAN M.

JOURNAL OF BUON , vol.22, no.2, pp.530-534, 2017 (SCI-Expanded, Scopus)

24. Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma

Akin S., Aksoy D. Y., AKIN S., KILIÇ M., Yetisir F., BAYRAKTAR M.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.47, no.6, pp.1723-1727, 2017 (SCI-Expanded, Scopus, TRDizin)

25. Symptomatic Adrenal Insufficiency due to Bilateral Adrenal Non-Hodgkin’s Lymphoma

AKIN Ş., Akın S., TUNCEL M., ERSÖZ G. N.

Turkish Journal of Endocrinology and Metabolism , vol.20, pp.108-110, 2016 (Scopus, TRDizin)

26. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience

Sarici F., BABACAN T., Buyukhatipoglu H., Balakan O., SEVER A. R., KERTMEN N., et al.

JOURNAL OF BUON , vol.21, no.4, pp.826-831, 2016 (SCI-Expanded, Scopus)

27. Interpretation of survival data: which graphical analysis is appropriate?

Dizdar O., AKIN S., HAYRAN M.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY , vol.8, no.4, pp.312, 2016 (SCI-Expanded, Scopus)

28. Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients

Ozen M., Gunduz M., ATEŞ Ö., BABACAN T., SEVER A. R., AKIN S., et al.

JOURNAL OF BUON , vol.21, no.4, pp.799-808, 2016 (SCI-Expanded, Scopus) Sustainable Development

29. Left laterality is an independent prognostic factor for metastasis in N3 stage breast cancer

Karatas F., Sahin S., Erdem G. U., ATEŞ Ö., BABACAN T., AKIN S., et al.

JOURNAL OF BUON , vol.21, no.4, pp.851-858, 2016 (SCI-Expanded, Scopus) Sustainable Development

30. Analysis of the Adjuvant Hormone Therapy Randomized Trial

Karakas Y., AKIN S., DİZDAR Ö., AKSOY S.

JOURNAL OF CLINICAL ONCOLOGY , vol.34, no.17, pp.2070-2071, 2016 (SCI-Expanded, Scopus)

31. Leg cramps associated with tamoxifen use - possible mechanism and treatment recommendations

Karatas F., Sahin S., BABACAN T., AKIN S., SEVER A. R., Altundag K.

JOURNAL OF BUON , vol.21, no.2, pp.520, 2016 (SCI-Expanded, Scopus)

32. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer

ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., et al.

JOURNAL OF BUON , vol.21, no.2, pp.375-381, 2016 (SCI-Expanded, Scopus) Sustainable Development

33. Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy

AKIN S., DİZDAR Ö., ÖZIŞIK L., TANRIOVER M., KAMISLI S., ERMAN M., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.3, pp.167-172, 2016 (SCI-Expanded, Scopus, TRDizin)

34. Insomnia caused by aromatase inhibitors; a therapeutic challenge in patients with breast cancer

Karatas F., Sahin S., BABACAN T., AKIN S., SEVER A. R., Altundag K.

JOURNAL OF BUON , vol.20, no.6, pp.1640, 2015 (SCI-Expanded, Scopus) Sustainable Development

35. Does eribulin mesylate cause recurrent transient diplopia?

Karatas F., Hacioglu B., AKIN S., BABACAN T., SEVER A. R., Altundag K.

JOURNAL OF BUON , vol.20, no.5, pp.1379, 2015 (SCI-Expanded, Scopus)

36. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer

BABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., et al.

TUMORI J , vol.101, no.4, pp.418-423, 2015 (SCI-Expanded, Scopus) Sustainable Development

37. Can aromatase inhibitors cause forgetfulness in women with breast cancer ?

Karatas F., AKIN S., BABACAN T., SEVER A. R., Altundag K.

JOURNAL OF BUON , vol.20, no.3, pp.935, 2015 (SCI-Expanded, Scopus) Sustainable Development

38. Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis

BABACAN T., Buyukhatipoglu H., Balakan O., KERTMEN N., Suner A., Sarici F., et al.

JOURNAL OF BUON , vol.20, no.2, pp.479-486, 2015 (SCI-Expanded, Scopus) Sustainable Development

39. How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?

Hacioglu B., AKIN S., BABACAN T., SEVER A. R., Altundag K.

FUTURE ONCOLOGY , vol.11, no.20, pp.2799-2801, 2015 (SCI-Expanded, Scopus) Sustainable Development

40. Comparison of three different induction regimens for nasopharyngeal cancer

KERTMEN N., AKSOY S., CENGİZ M., YAZICI G., KESKİN O., Babacan T., et al.

Asian Pacific Journal of Cancer Prevention , vol.16, no.1, pp.59-63, 2015 (SCI-Expanded, Scopus)

41. Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab

ATEŞ Ö., Sunar V., BABACAN T., AKIN S., KERTMEN N., Altundag K.

JOURNAL OF BUON , vol.20, no.1, pp.349, 2015 (SCI-Expanded, Scopus)

42. Clinical implications of intratumoral heterogeneity ofHER2gene amplification in locally advanced HER2-positive breast cancer patients

Hacioglu B., AKIN S., SEVER A. R., Altundag K.

FUTURE ONCOLOGY , vol.11, no.18, pp.2495-2497, 2015 (SCI-Expanded, Scopus) Sustainable Development

43. Molecular subtypes in patients with inflammatory breast cancer; A single center experience

KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., et al.

JOURNAL OF BUON , vol.20, no.1, pp.35-39, 2015 (SCI-Expanded, Scopus) Sustainable Development

44. Which sequence best protects the heart against trastuzumab and anthracycline toxicity An electron microscopy study in rats

KERTMEN N., AKSOY S., ÜNER A., ÖZGÜR Ö., keskin o., babacan t., et al.

Anticancer Research , 2015 (SCI-Expanded, Scopus)

45. Acute erythroid leukemia in a patient with chronic lymphocytic leukemia

GÜVEN D. C., BABACAN T., Sarici F., AKIN S., Altundag K., Turker A.

JOURNAL OF BUON , vol.19, no.4, pp.1127, 2014 (SCI-Expanded, Scopus)

46. Breast sarcoma: A rare malignancy

Gul G., BABACAN T., AKIN S., Sarici F., Altundag K.

JOURNAL OF BUON , vol.19, no.2, pp.577, 2014 (SCI-Expanded, Scopus)

47. A novel targeted therapy in breast cancer: Cyclin dependent kinase inhibitors

AKIN S., BABACAN T., Sarici F., Altundag K.

JOURNAL OF BUON , vol.19, no.1, pp.42-46, 2014 (SCI-Expanded, Scopus)

48. Nasopharyngeal sarcoidosis: a rare involvement

Akin S., Akin S., KARADAĞ Ö., KALYONCU U., Balci S., ÖZGEN MOCAN B.

RHEUMATOLOGY INTERNATIONAL , vol.32, no.5, pp.1407-1409, 2012 (SCI-Expanded, Scopus)

49. Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature

Serefhanoglu S., BÜYÜKAŞIK Y., GÖKER H., Akin S. C., Akin S., SAYINALP N., et al.

MEDICAL ONCOLOGY , vol.27, no.1, pp.55-58, 2010 (SCI-Expanded, Scopus)

Papers Presented at Peer-Reviewed Scientific Conferences 12

1. Kemoterapi Tedavisi Gören Kanser Hastalarında Fiziksel Aktivite ile Sağlık Okuryazarlığı, Yaşam Kalitesi ve Sosyal Destek Algısı Arasındaki İlişkinin Araştırılması

Karakaş O., İmece A. M., KUMBAROĞLU F. B., AKIN S., ATASAVUN UYSAL S.

19. ULUSLARARASI FİZYOTERAPİDE GELİŞMELER KONGRESİ, Ankara, Turkey, 09 April 2025, (Summary Text)

2. The Role of FDG PET/CT Detecting Bone Marrow Involvement in Non-Hodgkin's Lymphoma Patients

KUPIK O., Akin S., TUNCEL M., TÜRKER A., Kars A., Erbas B.

31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Düsseldorf, Germany, 13 - 17 October 2018, vol.45, (Summary Text)

3. The impact of the total size of lesions in multifocal multicentric breast cancer on survival

Karakaş Y., DİZDAR Ö., Akın S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., et al.

2016 ASCO Annual Meeting, 29 May - 03 June 2016, (Full Text) Sustainable Development

4. Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma

ATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., et al.

2016 ASCO Annual Meeting, 29 May - 03 June 2016, (Full Text)

5. The impact of the total size of lesions in multifocal/multicentric breast cancer on survival.

Karakas Y., Dizdar O., Akin S., Ates O., Sendur M. A. N., Aksoy S., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34, (Summary Text) Sustainable Development

6. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer

Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al.

ASCO Annual Meeting, 29 May - 02 June 2015, (Full Text) Sustainable Development

7. Correlation of educational status and clinicopathological characteristics of breast cancer: A single center experience.

Diker O., Babacan T., Buyukhatipoglu H., Kertmen N., Balakan O., Sever A. R., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text) Sustainable Development

Metrics

Publication

Publication (WoS)

Publication (Scopus)

Citation (WoS)

118

H-Index (WoS)

Citation (Scopus)

H-Index (Scopus)

Project

Open Access

UN Sustainable Development Goals

Publications & Works